• Dry eye disease (DED) (keratoconjunctivitis sicca) is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface (1, 2, 3).
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• Currently available medical treatment options include artificial tear products, lubricants, topical steroids and ciclosporin A (CsA). Artificial tears (AT) aim to alleviate mild to moderate symptoms by replacing or retaining moisture on the ocular surface, providing only short-term relief, and requiring frequent dosing throughout the day. The preservative in many artificial tear products often causes eye irritation.
• Ikervis ® is a sterile, positively charged, oil-in water, unpreserved ophthalmic emulsion that contains the active ingredient CsA Ph.
Eur. at a concentration of 1 mg/mL (0.1% w/w). CsA has an antiinflammatory effect on the cornea and the conjunctiva thereby reducing inflammation in the eye (4). The emulsion formulation is specifically designed to prolong the residence time of each eye drop on the epithelial layer of the eye.
• Ikervis ® has been shown to be effective in the composite efficacy endpoint (corneal fluorescein staining improvement of at least 3 grade on the modified Oxford Scale and improvement of at least 30% of the Ocular Surface Disease Index) which measures the effect of ciclosporin on both signs and symptoms (5) (Figure 1 ).
• The de novo economic evaluation, a cost utility analysis, utilises a Markov framework to assess the cost-effectiveness of Ikervis plus artificial tear substitutes (AT) compared to the AT in adult patients with DED and severe keratitis whose disease had not adequately responded to tear substitutes. A 30 year time horizon and monthly cycles were used. Both costs and benefits were discounted at 3.5% p.a.
• The model captures three frontline therapy states;
o Response (an OSDI improvement from baseline of ≥30% and a CFS improvement from baseline ≥3), o non-response, and o death.
• Responders have a higher Health Related Quality of Life (HRQoL) than non-responders.
• Evidence for the efficacy of Ikervis and patient utilities were derived from the SANSIKA (5) and SICCANOVE (6) randomised controlled trials in adult patients with DED and severe keratitis.
• A visual representation of the model can be seen in Figure 2 .
• Eligible patients enter 'treatment induction' where they receive six months of therapy (Ikervis + AT or AT alone).
• Responders to treatment continue on therapy until treatment is no longer efficacious and active treatment is ceased or, in a small number of patients, temporary punctal plugs are trialled.
• A small proportion of patients will progress to having the treatment made permanent if they respond well to the temporary plugs, while the remainder returns to using artificial tears alone.
• Table 1 summarises the key inputs of the model.
• The base case analysis shows that, compared to AT alone, Ikervis + AT results in an incremental lifetime cost to the UK NHS of £714 per patient (£15,997 minus £15,283) but offers an additional 0.037 QALYs (9.744 minus 9.707).
• From Table 2 it can be seen that the incremental costeffectiveness ratio (ICER) is therefore £19,156 per QALY gained.
• The cost-effectiveness plane arising from the probabilistic analysis is presented in Figure 3 and the associated costeffectiveness acceptability curve in Figure 4 .
• Probabilistic sensitivity analysis confirms that Ikervis® produces a benefit to patients, generating a utility gain compared with artificial tears in all 1000 simulations.
• At a cost-effectiveness threshold of £20,000 per QALY gained, Ikervis® is cost-effective in approximately 46% of simulations.
This increases to 71% at £30,000 per QALY gained. The probabilistic ICER of Ikervis is £18,835 per QALY gained.
• A number of scenario analyses (table 3) • Against a baseline utility of 0.66 for non-responders to treatment, Figure 5 presents graphically the ICER of Ikervis with a range of alternative response utilities. Ikervis becomes cost-effective at a threshold of £30,000 per QALY gained at utilities around 0.71 (i.e. an incremental gain for responders of 0.05), a smaller value than that observed in both SANSIKA and the published literature (7, 8).
• Univariate deterministic sensitivity analysis ( Figure 6 ) highlighted that uncertainty surrounding the absolute utility value for treatment responders has the greatest impact on the ICER.
• In summary, there is robust evidence from two clinical trials (SANSIKA and SICCANOVE (5, 6)) of the efficacy of Ikervis ® in patients with DED and severe keratitis compared to AT without ciclosporine.
• These results demonstrate the improvement in the composite CFS-OSDI endpoint (an OSDI improvement from baseline of ≥30% and a CFS improvement from baseline ≥3) with Ikervis ® , indicating a clinically relevant therapeutic benefit in comparison to AT without ciclosporine.
• The base-case ICER of £19,156 per QALY gained is compelling evidence of the cost-effectiveness of Ikervis ® compared with AT at the lowest cost-effectiveness threshold, of £20,000 per QALY gained.
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